Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH was delisted on the 25th of March, 2025.
19 hedge funds and large institutions have $1.8M invested in Cyclo Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 3 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less funds holding
Funds holding: 22 → 19 (-3)
37% less capital invested
Capital invested by funds: $2.84M → $1.8M (-$1.04M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$152K |
| 2 |
BlackRock
New York
|
+$24K |
| 3 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$3K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$784 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$405 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECG
EPIQ Capital Group
San Francisco,
California
|
-$77.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$31.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$23.1K |
| 4 |
Renaissance Technologies
New York
|
-$17K |
| 5 |
PGAM
Princeton Global Asset Management
Princeton,
New Jersey
|
-$300 |
CYTH Hedge Fund Activity: Q3 2024 in Review
19 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q3 2024, worth a combined $1.8M — down 37% from $2.84M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CYTH and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $152K. The largest seller was EPIQ Capital Group, cutting an estimated $77.8K.
- 19 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q3 2024, down from 22 in Q2 2024.
- Funds reported $1.8M of Cyclo Therapeutics, Inc. Common Stock stock for Q3 2024, down 37% quarter-over-quarter.
- 0 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q3 2024 and 3 closed out, a net change of -3 holders.
- The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q3 2024 was Vanguard Group, an estimated $152K added.
- The largest Cyclo Therapeutics, Inc. Common Stock seller in Q3 2024 was EPIQ Capital Group, an estimated $77.8K sold.
Based on aggregated 13F filings for Q3 2024.